When working with isoniazid resistance, the ability of Mycobacterium tuberculosis to survive despite treatment with the antibiotic isoniazid. Also known as INH resistance, it poses a major hurdle for TB control programs worldwide.
The problem doesn’t exist in isolation. Tuberculosis, a contagious bacterial infection that primarily attacks the lungs but can affect other organs is the disease context, while multidrug‑resistant TB (MDR‑TB), TB strains resistant to at least isoniazid and rifampicin represents the clinical escalation that often follows unchecked isoniazid resistance. The key genetic driver is a mutation in the katG gene, which encodes the enzyme that activates isoniazid inside the bacterial cell. When katG is altered, isoniazid can’t be converted to its active form, so the bacterium survives. Another common player is the inhA promoter mutation, a change that increases the production of the target enzyme, reducing drug effectiveness. These genetic changes encompass the semantic triple: *Isoniazid resistance* **encompasses** *katG mutations*. Detection now relies on rapid molecular testing such as GeneXpert or line‑probe assays, which **influence** early identification of resistance and guide clinicians toward alternative regimens. Treatment pathways require drugs that bypass the blocked mechanism—fluoroquinolones, ethionamide, or newer agents like bedaquiline—showing that *effective management* **requires** *alternative drug combinations*.
Below you’ll find a curated set of articles that dive into practical aspects of dealing with resistant TB and related drug issues. From dosage guides for second‑line antibiotics to safety tips for purchasing generics online, the collection covers everything you might need to navigate the challenges of isoniazid‑resistant infections. Whether you’re a patient looking for clear advice or a health professional seeking up‑to‑date references, the posts ahead give actionable insights that build on the concepts explained here. Let’s explore the resources and see how they can help you tackle resistance head‑on.
A clear, practical comparison of Isoniazid with Rifampin, Ethambutol, Pyrazinamide, and newer TB drugs, covering efficacy, side effects, resistance and cost for clinicians.
© 2025. All rights reserved.